A simple method to improve the dissolution of repaglinide and exploration of its mechanism  by Zhu, Zhaolu et al.
ww.sciencedirect.com
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 1 8e2 2 5Available online at wScienceDirect
journal homepage: ht tp: / /ees.elsevier .com/ajps/default .aspOriginal Research PaperA simple method to improve the dissolution
of repaglinide and exploration of its mechanismZhaolu Zhu a, Tianzhi Yang b, Yanan Zhao a, Nannan Gao a,
Donglei Leng a, Pingtian Ding a,*
a School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China
b Department of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, 1 College Circle, Bangor,
ME 04401, USAa r t i c l e i n f o
Article history:
Received 13 March 2014
Received in revised form
25 June 2014
Accepted 25 June 2014
Available online 14 July 2014
Keywords:
In vitro dissolution
Repaglinide
Meglumine
Solubilization
Molecular complex* Corresponding author. Tel.: þ86 24 23986305
E-mail addresses: dingpingtian@qq.com, zzl
Peer review under responsibility of Shenyan
Production and hosting by El
http://dx.doi.org/10.1016/j.ajps.2014.06.004
1818-0876/© 2014 Shenyang Pharmaceuticala b s t r a c t
In the present study, a simple and rapid method was developed to improve the in vitro
dissolution of repaglinide, an oral antidiabetic drug, which was based on addition of
meglumine in 50% (v/v) ethanol to dissolve repaglinide, and the drug dissolved in meglu-
mine/50% ethanol was used directly with a binder to prepare tablets. The mechanism of
solubilization of repaglinide by meglumine was studied by using infrared spectrum (IR),
ultraviolet (UV) measurement through dual wavelength, differential scanning calorimetry
(DSC) and X-ray powder diffraction methods. Dissolution tests of repaglinide tablets were
performed in the media with different pH values and the repaglinide concentrations were
analyzed by High Performance Liquid Chromatography (HPLC) method. The solubility data
showed that with the meglumine concentration increasing, the solubility of repaglinide
was increased. Meanwhile, tablets with the molar ratio of repaglinide and meglumine 1:2
(n/n) resulted in a significant increase in dissolution compared to the repaglinide tablets
without using meglumine, and nearly equal to the commercial preparations of Novo-
Norm®, which concluded that meglumine had a great role in promoting the dissolution of
repaglinide. The results of IR and UV dual wavelength methods suggested the formation of
repaglinideemeglumine (REPeMEG) molecular complex. DSC results showed that the
melting peak of repaglinide disappeared in the REPeMEG coprecipitate, which indicated
that repaglinide was stable when existing at amorphous or molecular state. The experi-
ment of X-ray powder diffraction showed that with the solubilization of meglumine, the
crystal diffraction peak of repaglinide disappeared, which further inferred that repaglinide
was formed complexes with meglumine. It was demonstrated that the method of
improving repaglinide with meglumine was reliable and could be suitable for repaglinide
tablets production in industry. This study also provides a feasible way to enhance the, þ86 13940375008 (mobile); fax: þ86 24 23986305.
06202330@163.com (P. Ding).
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rights reserved.1. Introduction
Repaglinide (REP), 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-
piperidinyl) phenyl] butyl] amino]-2-oxoethyl] benzoic acid
(shown in Fig. 1) is an oral antidiabetic drug, which was
developed to specifically control meal-related glucose fluctu-
ations in patients with type 2 diabetes mellitus by stimulating
insulin secretion from the pancreas [1]. The action of REP is
binding to the specific receptors on b-cells in pancreatic islets,
making the potassium channels closed, causing the cell
membrane depolarized, and at last resulting in the stimula-
tion of insulin secretion.
With a low water solubility (34 mg/ml at 37 C) and high
lipophilicity (logP ¼ 3.97), REP belongs to Biopharmaceutics
Classification System (BCS) class Ⅱ drug [2]. So there are
challenges on increasing the dissolution and bioavailability of
the drug. Recently, a few formulation approaches have been
developed to improve its dissolution and oral absorption,
including using HP-b-CD inclusion [3] and solid dispersion [4].
However, there is a certain degree of difficulty in formulation
and preparation technologies to improve the dissolution of
REP by the methods mentioned above, which brings a great
challenge to the preparation production in industry. There-
fore, a simple method that would not only improve the
dissolution of REP, but also be suitable for industrial produc-
tion is much needed.
Meglumine (MEG) is a type of small molecular solubilizer,
whose structure is shown in Fig. 2. Since it is non-toxic and
can improve the solubility of a number of poorly soluble drugs
greatly, it is widely used in many formulations. Due to the
alkaline amine in MEG and the acid carboxyl group in REP, it
could be hypothesized that these two substances can generate
molecular complexes, which will increase the solubility of
REP. It has been reported that MEG could form molecular
complexes with drugs in solution to achieve the solubilization
effect, which was based on the principle of electrostaticf REP.attraction due to electron- rich carbonyl oxygen in drugs and
positively charged amino in MEG [5]. With the amino group in
the molecular structure, MEG also makes contributions to the
stabilization of some drugs that are easily degraded by alde-
hydes [6]. Since the solubility of REP in water is very low,
practically insoluble, higher concentration of ethanol can be
used as solvent of REP. However, unfavorable impact exists
when higher concentration of ethanol used in production of
REP preparations. Therefore, we need to choose a suitable
solvent system and optimize the concentration of MEG as a
solubilizer to improve the solubility of REP. In this study, the
method of MEG combined with low concentration of ethanol
to improve the solubility of REP was established and the re-
sults showed that the drug achieved a complete release in vitro
dissolution test. In addition, the solubilization mechanism of
MEG for REP tablet preparation was studied.2. Materials and methods
2.1. Materials
REP (Tianjin Jinkang Pharmaceutical Co. Ltd. China) was used
as a model drug, MEG (Wuxi Shanhe Pharmaceutical Co. Ltd.
China) as a solubilizer was added to promote drug dispersion,
povidone (PVP K30), sodium carboxymethyl starch (CMS-Na)
and magnesium stearate (MS) (Anhui Shanhe Pharmaceutical
Co. Ltd. China) were selected as adhesives, disintegrants and
lubricants respectively. Microcrystalline cellulose (MCC)
pH101 (Asahi Kasei Co. Ltd Japan) were used as fillers. Opadry®
XY (Shanghai Colorcon Coating Technology Co., Ltd) was used
as film coating material to avoid light and moisture. Novo-
Norm® (Novo Nordisk Inc. Denmark) was selected as a refer-
ence formulation for the dissolution test. All other solvents
used were of analytical grade.
2.2. Determination of REP concentration
An accurate and precisemethodwas established to determine
the concentration of REP on an HPLC (Waters e2695-2489,
Empower chromatography workstation, USA). A C18 column
(150 mm  4.6 mm, 5 mm) was used and the mobile phase ofFig. 2 e Chemical structure of MEG.
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was run at the flow rate of 1.0ml/min. Thewavelengthwas set
at 240 nm.2.3. Determination of solubility of REP in different
solubilizing systems
The solubilization ability of MEG was studied by measuring
the solubility of REP in different systems, including water so-
lution with different concentrations of MEG (0.1%, 1%, 2%, 5%,
10%, w/v), various concentrations of ethanol (10%, 30%, 50%,
70%, 95%, v/v), and various concentrations of MEG (0.1%, 1%,
2%, 5%, 10%w/v) in 50% (v/v) ethanol. The measurement of
solubility was conducted by a thermostat oscillator (HZQ- C,
Harbin Dongming Medical Factory) at 37 C according to pre-
vious literature reported [7]. Excess REP was added to different
solubilizing systems, whichwere then put into the thermostat
oscillator. REP solution samples were collected at regular time
intervals until the concentration of REP remained unchanged,
and REP concentrations were analyzed by the HPLCmethod as
described above. All solubility experiments were performed in
triplicate.2.4. Preparation of test tablets with MEG
REP is used in a small quantity in the tablet preparation, and
has unfavorable physical properties, such as sticky, lumpy
and not easy to disperse. It makes conventional methods by
adding other excipients andmixing to form tablet not feasible,
and is likely to cause unacceptable content uniformity prob-
lems. So REP generally needs to be dissolved in an appropriate
solvent system and then combined with adhesives.
MEG (0.085 g) was dissolved in 6ml of 50% (v/v) ethanol. REP
(0.1 g) was added into the MEG/ethanol solution, and agitated
until completely dissolved. PVP K30 was added into the drug
solution under vigorous stirring continuously until the final
mixturecontained5.0%PVPK30.ThenMCC(9.2g)wasaddedas
the carrier. A wet granulation of the above ingredients was
prepared by passing through a 30-mesh screen, then dried at
60Cfor60min,andscreenedthrougha30-meshscreen.Finally
CMS-Na (0.3 g) and MS (0.065 g) were added into the granules,
mixed well and compressed into tablets, which made the final
preparations contain REP and MEG by a ratio of 1:2 (n/n). A
Single-punch tablet press machine (TPB, Shanghai First Phar-
maceutical Machinery Factory) was used in the study.2.5. Preparation of control tablets without MEG
In the absence of MEG, the required dose of REP was not sol-
uble in 6 ml of 50% (v/v) ethanol. Therefore, three control
tablets without MEG were prepared as follows: control tablets
1: the required dose of REP and PVP K30 were uniformly
dispersed in 50% (v/v) ethanol; control tablets 2: the required
dose of REP and PVP K30 were dissolved in anhydrous ethanol;
control tablets 3: without PVP K30, only the required dose of
REP was dissolved in anhydrous ethanol. The preparation
methods afterwards of the control tablets were the same as
the tablets containing MEG.2.6. Dissolution tests
Dissolution tests (six replicates) of experimental tablets (test
tablets with MEG and control tablets without MEG) and
reference tablets (commercial tablets NovoNorm®) were
respectively performed in 5 different dissolution media,
including 0.1 mol/l HCL (pH 1.0), acetate buffer (pH 4.5),
phosphate buffer (pH 6.8 and pH7.4) and distilled water (37 C,
V ¼ 100 ml), using the dissolution tester (ZRS-8G, Tianjin
Tianda Tianfa Technology Co. Ltd) with the paddle rotating at
50 revolutions per minute (rpm). The amount of drug added to
the dissolution vessel was equivalent of 1 mg REP. Samples
(5 mL) were obtained from the dissolution cups at the time of
5, 10, 15, 20, 30, 45, 60min and filtered for analysis.Meanwhile,
fresh medium with the same temperature and volume was
added into the dissolution cups. Then the REP content was
assessed by the validated HPLCmethod, and the accumulative
dissolution and similarity factor (f2) between test preparations
and reference preparations were calculated. The calculation
formula [8] which was recommended by Food and Drug
Administration (FDA) was shown below:
f2 ¼ 50 log
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In which, Ti and Ri represent the average dissolution at
each sampling time point of test preparations and reference
preparations respectively, n is the number of sampling time
points. If 50  f2  100, the dissolution profile of the two
preparations showed no significant difference, if f2 < 50, it was
considered statistically significant difference.
2.7. Solubilization mechanism study of MEG for REP
preparation
2.7.1. Sample preparations
MEG (85 mg) was dried to constant weight and then added to
6 ml of 50% ethanol. 100 mg REP was subsequently added into
the MEG/50% ethanol and stirred until REP was completely
dissolved. The solution was then blew to dry with nitrogen at
40 C, which resulted in a solid REPeMEG coprecipitate.
Granules containing REP were prepared according to the
method of tablets preparation. A homogenous REP and MEG
physical mixture was prepared by simply mixing 85 mg MEG
with 100 mg REP in a mortar.
2.7.2. Characterization of REPeMEG molecular complex by IR
REP, MEG and REPeMEG coprecipitate were analyzed on an IR
spectrophotometer (FT-IR, Spectrum 1000, Perkin Elmer Co.,
Ltd U.S). The IR spectra of the samples were recorded in the
wavelength range 4000e400 cm1 in KBr pellets.
2.7.3. Determination of the composition of the REPeMEG
molecular complex by UV dual wavelength detection
Dual wavelength absorbance was determined on an ultravio-
let- visible spectrophotometer (UV-1801, Beijing Rayleigh
Analytical Instruments Co., Ltd) as previously described [5,6].
A series of solutions were prepared with the same total
quality, but different mass ratio of REP and MEG. Two equal
Table 1 e Solubility of REP in different
concentration of ethanol at 37 C (n ¼ 3).
Concentration
of ethanol (v/v, %)
Solubility of
REP (mg/ml)
95 120.3 ± 0.3
70 14.96 ± 0.04
50 1.270 ± 0.007
30 0.061 ± 0.001
10 0.028 ± 0.000
Table 3 e Solubility of REP in 50% (v/v)
ethanol with different concentration of
MEG at 37 C (n ¼ 3).
Concentration of
MEG (w/v, %)
Solubility of
REP (mg/ml)
0.1 4.14 ± 0.03
1.0 24.16 ± 0.12
2.0 45.03 ± 0.41
5.0 102.3 ± 1.0
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absorbance determination. The absorbance of the solutions
was determined under these two absorbance wavelength
respectively, and the differential absorption value (DA) was
calculated by the principle of equal absorption elimination
method with double wavelength.
2.7.4. Characterization of REPeMEG molecular complex by
DSC
MEG, REP, REPeMEG physical mixture, REPeMEG coprecipitate
and particles which were obtained by wet granulation were
analyzed by differential scanning calorimeter (DSC-1, Met-
tlereToledo Co., Ltd Swiss). DSC curves of the samples were
recorded in the temperature range of 25 Ce170 C, at a
heating rate of 10 C/min. Themeasurements were performed
in closed aluminum containers under a nitrogen atmosphere.
2.7.5. Characterization of REPeMEG molecular complex by
X-ray powder diffraction method
MEG, REP, REPeMEG physical mixture, REPeMEG coprecipitate
and particles which were obtained by wet granulation were
analyzed by X-ray powder diffraction (Rigaku Geigerflex Co.,
Ltd Japan) under the following conditions: the samples were
exposed to graphite monochromated CuKa radiation. The
voltage and the strength of the electric current were 40 KV and
300 mA, respectively.3. Results and discussion
3.1. Solubilization effect of MEG on REP
The solubilities of REP in different concentrations of ethanol
were shown in Table 1. The results indicated that decreasing
the concentration of ethanol resulted in a significant decrease
in the solubility of REP. Table 2 and Table 3 revealed the effect
of MEG on the solubility of REP in water and 50% (v/v) ethanol.
MEG played a very important role in increasing the solubilityTable 2 e Solubility of REP in water with
different concentration of MEG at 37 C
(n ¼ 3).
Concentration
of MEG (w/v, %)
Solubility of
REP (mg/ml)
0.1 1.21 ± 0.01
1.0 3.61 ± 0.03
2.0 7.31 ± 0.06
5.0 10.97 ± 0.08of REP, and the solubilization ability of MEG in 50% (v/v)
ethanol was significantly superior to that in water. Although
the solubility of REP (120 mg/ml) is excellent in 95% (v/v)
ethanol,much concernwill be raised since high concentration
of ethanol may bring problems in the follow-up examination
of organic solvent content, and cause safety issues. At last,
50% (v/v) ethanol solution was chosen as the solvent of REP in
order to improve its dissolution and meet the industrial pro-
duction requirements at the same time.
3.2. Dissolution tests
Determination of dissolution profiles at a variety of pH value
conditions has become an important means of reflecting the
intrinsic quality of solid preparations. For poorly soluble
drugs, the rate-limiting process of drug absorption is the
dissolution rate and extent from the particles and accessories
[9]. Therefore, 5 dissolution media with different pH values
were used for studying the dissolution of REP.
From the results of dissolution experiments that were
shown in Table 4, it could be found obviously that the cu-
mulative dissolution of test tablets containing MEG were all
reached 95% or more under different pH conditions, which
acted the same as the reference tablets (NovoNorm®). The
similarity factors (shown in Fig. 3) of dissolution profile were
50%e70%.However, it was entirely different in the tablets
without MEG and the cumulative dissolution of REP from
control tablets 1 was less than 60%.
Additional experiments on the control tablets 2 and 3 were
carried out to test the effect of PVP K30 on the dissolution of
REP. The results showed the cumulative dissolution of control
tablets 2 and 3 were 73.6% and 74.1%, respectively, which
means PVP K30 had little contribution to the dissolution of
REP. We also found the dissolution of tablets prepared by
dissolving REP in anhydrous ethanol was significantly
improved, which might be because the dissolved REP in tab-
lets had a better dispersion. However, it is not feasible to useTable 4 e Cumulative dissolution of REP in various
systems with different pH values at 37 C (n ¼ 6).
Medium Dissolution %
Reference
tablets
Test
tablets
Control
tablets 1
pH 1.0 101.9 ± 1.1 100.8 ± 1.1 53.4 ± 1.0
pH 4.5 95.4 ± 1.2 95.4 ± 0.9 43.3 ± 0.4
pH 6.8 96.3 ± 0.9 96.9 ± 1.0 44.9 ± 0.6
pH 7.4 99.4 ± 1.1 99.8 ± 1.2 49.4 ± 1.0
Distilled water 95.3 ± 1.3 95.4 ± 1.4 35.4 ± 0.4
Fig. 3 e Dissolution curves of REP in various media with different pH values.
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experiments, we can conclude it was MEG, not PVP K30 that
made a significant contribution to the dissolution of REP.
It was also found that dissolutionmedia had certain effects
on the dissolution characteristics (shown in Fig. 4). As REP is
an acid-base ampholyte with two protonation sites, whose
pKa1 and pKa2 were 4.16 and 6.01 separately, at the isoelectric
pH (5.50) condition, two neutral forms of REP (zwitterionic and
uncharged) exist which result in the ampholytic nature of the
drugmolecule and its U-shape solubility profile with the lower
solubility at pH 5e6 [2].3.3. Solubilization mechanism of MEG
3.3.1. Characterization ofREPeMEGmolecular complexesby IR
There were distinct differences between the IR spectra of
REPeMEG coprecipitate and that of REP or MEG alone (Fig. 5).
As could be seen in Fig. 5, the main characteristic peaks of
amine are VNH at 3500e3300 cm
1, dNH at 1650e1510 cm
1 and
VCeH at 1360e1020 cm
1. The VCeN peaks of fatty amine can be
located around 1250e1020 cm1, while theVOH andVCeO peaks
of alcoholic hydroxyl group can be found at 3500e3200 cm1(s,
wide) and 1260e1000 cm1(s). The IR spectra illustrated the
Fig. 4 e Dissolution curves of REP from test preparation
with MEG.
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(Fig. 5. The characteristic absorption peaks of REP at 3307,
1687, 1637, 1566, 1215 cm1were clearly changed in the
coprecipitate. Among them, peaks of 3307 and 1215 cm1were
disappeared while peaks of 1687, 1637 and 1566 cm1 were
shifted to the low frequency region, which was due to the
electrostatic attraction of the carbonyl group and aromatic
ether bond. This proved the existence of interactions between
REP and MEG, and indicated a new type of substance e mo-
lecular complex was produced. Combined with the molecular
structure of REP andMEG, it could be inferred that electrostatic
attraction was generated between the carbonyl oxygen and
aromatic ether bond that rich in electron and positively
charged amino group.Fig. 5 e IR spectra of REP (A), MEG (B)3.3.2. Determination of the composition of the REPeMEG
molecular complexes by UV dual wavelength detection
The absorbance of MEG was found to be zero in 200e400 nm
wavelength range by the UV spectrophotometry, which
means that MEG absorbance can be neglected when the
REPeMEG coprecipitate was determined by the UV method.
But the absorption of REP and co precipitate were similar, so
double wavelength spectrophotometrywas applied to exclude
the impact of REP on the absorbance. Two equal absorption
wavelength of REP, 230 nm and 251 nm, were selected and the
difference absorbance DA under the two wavelengths was
calculated. DA would be only proportional to the concentra-
tion of the REPeMEGmolecular complex. It could be seen from
Fig. 6, when the mass ratio of REP and MEG was 54:46 (molar
ratio1:2) in solution, the maximum DA was obtained, which
suggested a new substance, REPeMEG molecular complex,
was formed by a molar ratio of 1:2.
3.3.3. CharacterizationofREPeMEGmolecular complexbyDSC
FromtheobtainedDSCcurves inFig. 7, themeltingpeaksofREP
andMEGwere135.7 C, 130.3 C, respectively.Due to thesimilar
melting points of REP and MEG, the absorption peaks in their
physical mixtures were accumulating. But themelting peak of
REP disappeared in the REPeMEG coprecipitate and the parti-
cles produced bywet granulation, which further suggested the
formation of molecular complex between REP and MEG.
3.3.4. Characterization of REPeMEG molecular complex by
X-ray powder diffraction method
In the X-ray powder diffraction spectrum (Fig. 8), MEG and REP
showed clear crystal diffraction peaks, and their physical
mixture showed the peaks superposition of the REP and MEG.and REPeMEG coprecipitate (C).
Fig. 6 e Absorptivities differences in different wavelength
(l1¼ 230 nm, l2 ¼ 251 nm) of solutions containing REP and
MEG.
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trum of the REPeMEG coprecipitate, indicating the formation
of molecular complex, since there is no diffraction charac-
teristic for amorphous material.Fig. 8 e X-ray powder diffraction spectra of MEG (A), REP (B),
REPeMEG physical mixture (C), REPeMEG coprecipitate (D)
and particles obtained by themethod of wet granulation (E).4. Conclusion
This study was performed to establish a simplifiedmethod for
preparing REP tablets by dissolving the drug in a MEG/50%
ethanol solubilizing system. The resulted REP tablets exhibi-
ted excellent dissolution profile in in vitro dissolution test.
Adding MEG in the formulation was proved to be an effective
method to achieve the desired release behavior and could be
advantageous in terms of increased bioavailability of REP. The
solubilization mechanism of MEG is by generating molecular
complex, which has been confirmed by various methods,
including IR, UV dual wavelength detection, DSC and X-ray
powder diffraction. It was concluded that MEG increased the
solubility of REP and enhanced the dissolution of REP from
tablets. Major advantages of the study can be summarized asFig. 7 e DSC curves of MEG (A), REP (B), REPeMEG physical
mixture (C), REPeMEG coprecipitate (D) and particles
obtained by the method of wet granulation (E).follows: (i) The dissolution of REP was increased significantly.
(ii) Simple preparation method was established, which is
suitable for industrial production. (iii) Studying the solubili-
zation mechanism and characterizing the molecular complex
by a variety of analytical instruments will provide a new train
of thought for the formulation works of other poorly soluble
drugs.
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